Targeting LIN28: a new hope in prostate cancer theranostics
Shrivastava, G
Aljabali, AAA
Shahcheraghi, SH
Lotfi, M
Shastri, MD
Shukla, SD
Chellappan, DK
Jha, NK
Anand, K
Dureja, H
Pabari, RM
Mishra, V
Almutary, AG
Alnuqaydan, AM
Charbe, N
Prasher, P
Negi, P
Goyal, R
Dua, K
Gupta, G
Serrano-Aroca, Á
Bahar, B
Barh, D
Panda, PK
Takayama, K
Lundstorm, K
McCarron, P
Bakshi, H
Tambuwala, MM
- Publisher:
- Future Medicine Ltd
- Publication Type:
- Journal Article
- Citation:
- Future Oncology
Closed Access
Filename | Description | Size | |||
---|---|---|---|---|---|
LIN 28_Cancer theranostics_fon-2021-0247.pdf | Published version | 3.22 MB | Adobe PDF |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Shrivastava, G | |
dc.contributor.author | Aljabali, AAA | |
dc.contributor.author | Shahcheraghi, SH | |
dc.contributor.author | Lotfi, M | |
dc.contributor.author | Shastri, MD | |
dc.contributor.author | Shukla, SD | |
dc.contributor.author | Chellappan, DK | |
dc.contributor.author | Jha, NK | |
dc.contributor.author | Anand, K | |
dc.contributor.author | Dureja, H | |
dc.contributor.author | Pabari, RM | |
dc.contributor.author | Mishra, V | |
dc.contributor.author | Almutary, AG | |
dc.contributor.author | Alnuqaydan, AM | |
dc.contributor.author | Charbe, N | |
dc.contributor.author | Prasher, P | |
dc.contributor.author | Negi, P | |
dc.contributor.author | Goyal, R | |
dc.contributor.author |
Dua, K https://orcid.org/0000-0002-7507-1159 |
|
dc.contributor.author | Gupta, G | |
dc.contributor.author | Serrano-Aroca, Á | |
dc.contributor.author | Bahar, B | |
dc.contributor.author | Barh, D | |
dc.contributor.author | Panda, PK | |
dc.contributor.author | Takayama, K | |
dc.contributor.author | Lundstorm, K | |
dc.contributor.author | McCarron, P | |
dc.contributor.author | Bakshi, H | |
dc.contributor.author | Tambuwala, MM | |
dc.date.accessioned | 2021-07-15T23:23:38Z | |
dc.date.available | 2021-07-15T23:23:38Z | |
dc.identifier.citation | Future Oncology | |
dc.identifier.issn | 1479-6694 | |
dc.identifier.issn | 1744-8301 | |
dc.identifier.uri | http://hdl.handle.net/10453/149883 | |
dc.description.abstract | <jats:p> The mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog LIN28B overexpression are associated with a number of tumors resulting in a remarkable increase in cancer aggression and poor prognoses. The current review aims to highlight recent work identifying the key roles of LIN28A and LIN28B in prostate cancer, and to instigate further preclinical and clinical research in this important area. </jats:p> | |
dc.language | en | |
dc.publisher | Future Medicine Ltd | |
dc.relation.ispartof | Future Oncology | |
dc.relation.isbasedon | 10.2217/fon-2021-0247 | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | 1112 Oncology and Carcinogenesis | |
dc.subject.classification | Oncology & Carcinogenesis | |
dc.title | Targeting LIN28: a new hope in prostate cancer theranostics | |
dc.type | Journal Article | |
utslib.for | 1112 Oncology and Carcinogenesis | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health/Graduate School of Health | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy | |
utslib.copyright.status | closed_access | * |
dc.date.updated | 2021-07-15T23:23:36Z | |
pubs.publication-status | Published online |
Abstract:
The mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog LIN28B overexpression are associated with a number of tumors resulting in a remarkable increase in cancer aggression and poor prognoses. The current review aims to highlight recent work identifying the key roles of LIN28A and LIN28B in prostate cancer, and to instigate further preclinical and clinical research in this important area.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph